Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.99−0.02 (-1.00%)
Close on Nov 12, 2026Market cap $73.19MP/E –Yield –
Fortress Biotech operating margin
Operating margin is operating income as a percentage of revenue.
Fortress Biotech's operating margin for the twelve months ending Jun 30, 2026 was -42.9%. For fiscal 2025 it was -111.0%, against -191.4% the year before. The highest annual figure on record is -111.0% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -111.0% | +80.4 |
| FY2024 | Dec 31, 2024 | -191.4% | −23.0 |
| FY2023 | Dec 31, 2023 | -168.4% | +100.3 |
| FY2022 | Dec 31, 2022 | -268.8% | +5.3 |
| FY2021 | Dec 31, 2021 | -274.1% | −67.3 |
| FY2020 | Dec 31, 2020 | -206.7% | +95.8 |
| FY2019 | Dec 31, 2019 | -302.5% | +143.8 |
| FY2018 | Dec 31, 2018 | -446.4% | +74.3 |
| FY2017 | Dec 31, 2017 | -520.7% | −122.0 |
| FY2016 | Dec 31, 2016 | -398.7% | +5456.5 |
| FY2015 | Dec 31, 2015 | -5855.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -53.5% | +168.8 |
| Q1 FY2026 | Mar 31, 2026 | -48.3% | +121.6 |
| Q4 FY2025 | Dec 31, 2025 | -29.8% | +127.9 |
| Q3 FY2025 | Sep 30, 2025 | -38.6% | +112.4 |
| Q2 FY2025 | Jun 30, 2025 | -222.2% | −35.7 |
| Q1 FY2025 | Mar 31, 2025 | -169.9% | +110.8 |
| Q4 FY2024 | Dec 31, 2024 | -157.6% | −59.3 |
| Q3 FY2024 | Sep 30, 2024 | -151.0% | −111.4 |
| Q2 FY2024 | Jun 30, 2024 | -186.5% | +101.6 |
| Q1 FY2024 | Mar 31, 2024 | -280.6% | +193.0 |
| Q4 FY2023 | Dec 31, 2023 | -98.3% | +234.7 |
| Q3 FY2023 | Sep 30, 2023 | -39.6% | +267.4 |
| Q2 FY2023 | Jun 30, 2023 | -288.2% | −18.5 |
| Q1 FY2023 | Mar 31, 2023 | -473.6% | −276.1 |
| Q4 FY2022 | Dec 31, 2022 | -333.1% | +6.2 |
| Q3 FY2022 | Sep 30, 2022 | -307.0% | −70.2 |
| Q2 FY2022 | Jun 30, 2022 | -269.6% | −29.5 |
| Q1 FY2022 | Mar 31, 2022 | -197.6% | +61.5 |
| Q4 FY2021 | Dec 31, 2021 | -339.2% | −162.5 |
| Q3 FY2021 | Sep 30, 2021 | -236.8% | +6.4 |
| Q2 FY2021 | Jun 30, 2021 | -240.2% | +28.4 |
| Q1 FY2021 | Mar 31, 2021 | -259.1% | −92.4 |
| Q4 FY2020 | Dec 31, 2020 | -176.8% | +96.2 |
| Q3 FY2020 | Sep 30, 2020 | -243.2% | −12.5 |
| Q2 FY2020 | Jun 30, 2020 | -268.5% | +4.9 |
| Q1 FY2020 | Mar 31, 2020 | -166.7% | +336.8 |
| Q4 FY2019 | Dec 31, 2019 | -273.0% | +185.4 |
| Q3 FY2019 | Sep 30, 2019 | -230.7% | +314.6 |
| Q2 FY2019 | Jun 30, 2019 | -273.4% | +99.3 |
| Q1 FY2019 | Mar 31, 2019 | -503.4% | +75.4 |
| Q4 FY2018 | Dec 31, 2018 | -458.4% | −52.4 |
| Q3 FY2018 | Sep 30, 2018 | -545.2% | +716.6 |
| Q2 FY2018 | Jun 30, 2018 | -372.7% | +206.2 |
| Q1 FY2018 | Mar 31, 2018 | -578.9% | +109.6 |
| Q4 FY2017 | Dec 31, 2017 | -406.0% | −182.3 |
| Q3 FY2017 | Sep 30, 2017 | -1261.9% | +500.2 |
| Q2 FY2017 | Jun 30, 2017 | -578.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -688.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -223.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -1762.1% | – |
See a number that looks wrong?